Abstract. The aim of this study was to observe the inhibitory and therapeutic effects of small interfering RNA (siRNA) targeting Livin in EJ human bladder cancer cells. Specific siRNA targeting Livin was synthesized and transfected into EJ human bladder cancer cells treated or not treated with mitomycin-C (MMC). Livin mRNA and protein, as well as proliferation and apoptosis of EJ cells was examined with reverse transcription-polymerase chain reaction, western blotting, Cell Counting Kit-8 assay and flow cytometry, respectively. The results indicated that the expression of Livin mRNA and protein in EJ cells was significantly decreased by siRNA Livin. The proliferation of EJ cells was significantly inhibited by treatment with MMC and transfection of siRNA Livin. The inhibition of cell proliferation by treatment with MMC was further enhanced by transfection of siRNA Livin. The apoptotic rate of cells transfected with siRNA Livin and treated with MMC was significantly higher than those cells receiving a single transfection of siRNA Livin and single treatment of MMC. In conclusion, the present study demonstrates that transfection of siRNA Livin induces growth suppression and apoptosis in EJ human bladder cancer cells, and increases the chemotherapeutic sensitivity of cells to MMC.

Introduction

As a novel member of the inhibitor of apoptosis protein, Livin has been demonstrated to promote cellular proliferation and result in the resistance of tumors to chemotherapeutic medications under overexpression conditions (1). Livin was also revealed to be involved in the apoptosis of human bladder cancer cells through caspase-3 (2) and closely associated with recurrent bladder cancer, indicating the significance of Livin in the treatment of bladder cancer (1,3). Mitomycin-C (MMC) is a widely used antitumor chemical and is suggested to be useful in treating non-invasive bladder tumors (4), while the suppression of Livin may increase the apoptosis of bladder cancer T24 cells induced by MMC (5). This suggests a potential correlation of Livin inhibition with antitumor medications in tumor therapy.

RNA interference (RNAi), including short interfering RNA (siRNA) and short hairpin RNA, is one newly developed technology to silence post-transcriptional genes and is widely used in biopharmaceutical studies (6). Through siRNA and lipofection techniques, the present study delivered specific siRNA targeting Livin into EJ human bladder carcinoma cells to measure the expression of Livin in transfected cells, the effect of siRNA Livin on the apoptosis of EJ cells and the sensitivity of EJ cells to chemotherapeutic medication. This study is expected to provide a further theoretical and experimental basis for the use of chemotherapy in bladder carcinoma.

Materials and methods

Design of specific siRNA targeting Livin. In accordance with GenBank, the common sequences of isomers (α, NM_139317 and β, NM_022161) of human Livin (AF311388) designed and synthesized by Shanghai GenPharma Company (Shanghai, China) were sense, 5'-GAGAGAGGUCCAGUCUGAATT-3' and antisense, 5'-UUCAGACUGGACCUCUCUCTT-3'. Non-targeting homologous genes were excluded through comparison with BLAST. Non-human complementary siRNA sequences (sense, 5'-UUCUCCGAACGUUGAGUACUGU-3' and antisense, 5'-ACGUGACACGUUGUGAATT-3') were used as negative controls and labeled with FAM fluorescence (negative control FAM).

Cell culture and transfection. EJ human bladder carcinoma cells (Nanjing KeyGen BioTech. Co. Ltd., Nanjing, China) were cultured in a 5% CO2 incubator at 37°C with RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. EJ cells from the logarithmic phase were inoculated in 6-well or 96-well plates containing RPMI-1640 medium. When the confluence reached 40-60%, the cells were assigned into different groups according to treatment: blank control group (without treatment), intervention group [with the same volume
of siRNA and Lipofectamine® 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), chemotherapy group [24 h treatment with 0.1 mg/ml MMC (Sigma-Aldrich, St. Louis, MO, USA)], or combination group (24 h siRNA transfection and 24 h treatment with 0.1 mg/ml MMC). Cells were transfected with negative siRNA or with Lipofectamine 2000 reagent alone. The transfection rate of cells was observed under inverted fluorescence microscope after 24-48 h (Fig. 1). Our preliminary experiments revealed that the transfection rate in the 6-well plate reached 70% under conditions of 3x10^5 cells/well, 100 pmol/well siRNA and 5 µl/well Lipofectamine 2000 reagent. Similarly, the transfection rate in the 96-well plate reached 70% under conditions of 4x10^3 cells/well, 5 pmol/well siRNA and 0.25 µl/well Lipofectamine 2000 reagent.

Measurement of Livin mRNA with semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). After 24 h of transfection, the cells were rinsed with phosphate-buffered saline (PBS) twice, then 1 ml TRIZol was added to the lyse cells. The total RNA was extracted according to the manual and its quantity was measured using a UV spectrophotometer (Beijing ComWin Biotech Co., Ltd., Beijing, China). cDNA was synthesized under conditions of 42°C for 40 min and 85°C for 5 min, and used as a template for the amplification of the Livin gene with pre-denaturation at 94°C for 2 min, 30 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec and extension at 72°C for 30 sec, then final extension at 72°C for 2 min. The sense and antisense primers of Livin and β-actin genes were 5'-GTGGATGGGCAGATCCTG-3' and 5'-CCTGTGCTGATGGCTGCTG-3' (resulting in the production of 214 bp), and 5'-AGGTGACAGCAGTCGGTGG-3' and 5'-CGAAGGCTCATCATTCAAAA-3' (resulting in the production of 300 bp), respectively, synthesized by Beijing AuGCT DNA-SYN Biotechnology Co. Ltd. (Beijing, China). Following the reaction, the PCR production was identified with electrophoresis in 1.5% sucrose and analyzed with a SensiAnsys gel-imaging system (LI-COR Biosciences, Lincoln, NE, USA). The expression of Livin mRNA was semi-quantitatively calculated using the optical density ratio of Livin and β-actin. The experiment was repeated three times.

Measurement of Livin protein with western blot analysis. Following 48 h of transfection, the EJ cells were removed from the medium, rinsed twice with pre-cooled PBS, mixed with 100 µl RIPA lysis buffer and 10 µl PMSF in an ice-bath for 10 min, and centrifuged at 12,000 rpm at 4°C for 10 min. The total cellular protein was collected and quantified with the protein, which was transferred to a polyvinylidene fluoride membrane using the semi-dry method and blocked with Tris-buffered saline and Tween-20 (TBST) solution containing 5% skimmed milk at room temperature for 2 h. Primary Livin antibody (1:500) and β-actin antibody (1:1000; both from Beijing ComWin Biotech Co., Ltd.) were added for incubation at 4°C overnight. The membrane was rinsed with TBST three times and horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit 1:2000; Beijing ComWin Biotech Co., Ltd.) were added for incubation at room temperature for 1 h. After washing, the membrane was developed with the enhanced chemiluminescence method and exposed under a photographic system. The optical density of Livin protein was compared with that of β-actin as an internal reference. The experiment was repeated three times.

Inhibition of Livin mRNA by siRNA. After 24 h of transfection with siRNA Livin, the expression intensity of Livin mRNA in the blank control, negative control, liposome and intervention group (siRNA Livin) was 0.271±0.032, 0.301±0.043, 0.292±0.036 and 0.024±0.011, respectively, indicating that siRNA Livin significantly inhibited the expression of Livin mRNA (P<0.01). There was no significant difference between the blank control, negative control and liposome group (P>0.05, Fig. 2A).

Inhibition of Livin protein by siRNA Livin. Western blot analysis further indicated that the Livin protein in EJ cells was significantly decreased following the decrease of gene transcription. After 48 h of transfection, the relative expression of Livin protein in the blank control, negative control, liposome and intervention group (siRNA Livin) was 0.515±0.038, 0.539±0.047, 0.521±0.043 and 0.070±0.016, respectively. The statistic analysis indicated that Livin protein in EJ cells was significantly decreased following transfection of siRNA Livin (P<0.01). There was no significant difference between the blank control, negative control and liposome group (P>0.05, Fig. 2B).
Inhibition of EJ cell proliferation by siRNA Livin. Measurement of CCK-8 indicated that the proliferation of EJ cells was inhibited by siRNA Livin. The inhibition in the combination group was significantly higher than in the single intervention and single chemotherapy group (P<0.01, Table I).

Promotion of apoptosis of EJ cells by siRNA Livin. The flow cytometry assessment indicated that apoptosis was promoted in the intervention group (15.29±1.64%), chemotherapy group (17.57±0.82%) and combination group (40.19±1.53%), when compared with the blank control group (1.18±0.47%; P<0.01).

Table I. Inhibition of proliferation of EJ cells in different groups (mean ± standard deviation).

<table>
<thead>
<tr>
<th>Groups</th>
<th>Optical density</th>
<th>Inhibition rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank control group</td>
<td>0.862±0.174</td>
<td>2.14±0.761</td>
</tr>
<tr>
<td>Intervention group</td>
<td>0.794±0.163</td>
<td>7.787±4.032*</td>
</tr>
<tr>
<td>Chemotherapy group</td>
<td>0.660±0.156</td>
<td>23.375±7.813*</td>
</tr>
<tr>
<td>Combination group</td>
<td>0.471±0.096</td>
<td>45.355±5.617*</td>
</tr>
</tbody>
</table>

*P<0.01 vs. combination group, **P<0.01 vs. blank control group; n=15 for each group.

Figure 1. EJ bladder carcinoma cells in blank control group (A) and transfected with negative siRNA Livin (B) under inverted fluorescence microscopy (magnification, x400).

Figure 2. Expression of Livin mRNA (A) and protein (B) in different groups after 24 and 48 h transfection with siRNA Livin. **P<0.01 represents the relative Livin mRNA expression in blank control, negative control or lipofectamine groups compared with siRNA-treated cells.
SONG et al: siRNA LIVIN ENHANCES ANTI-BLADDERS CANCER EFFECTS OF MITOMYCIN-C

Furthermore, the apoptotic rate in the combination group was significantly higher than in the single intervention and single chemotherapy group (P<0.01, Fig. 3).

Discussion

Bladder carcinoma is the most common malignant tumor of the urinary system and one of the 10 most common tumors of the whole body. Although there are multiple strategies of accessory intra-bladder perfusion with variable medications following surgery, the recurrence rate is still high, which is mainly due to the resistance of tumor cells to chemotherapeutic mediation (7). Therefore, finding new targeting sites and enhancing chemotherapeutic sensitivity are critical for the therapy of bladder carcinoma. Previous studies indicated that Livin is not expressed or expressed at low levels in most differentiated terminal tissues of adults, but overexpressed in a number of malignant tumors (8-10). Overexpression of Livin inhibits the apoptosis of tumor cells and leads to the resistance of tumors to pro-apoptotic factors (11,12). In addition, Livin is associated with the invasiveness of tumors and oncogenic phenotypes (13). These studies suggest that Livin is one potential targeting site for the therapy of bladder carcinoma.

siRNA is a small segment of RNA with specific length and structure (~21-23 bp). It binds to certain enzymes to form RNA-induced silencing complex which specifically binds to and cuts the homologous regions of mRNA expressed by exogenous genes, resulting in the degradation of specific mRNA (14,15). siRNA has previously been used in biological experiments which have led to the development of new pathways of tumor therapy, due to siRNAs features of strong specificity, high efficiency and simple operation (2,16). The present study indicated that siRNA Livin inhibited the proliferation and enhanced the apoptosis of EJ human bladder carcinoma cells, suggesting the effectiveness and practicality of siRNA Livin in treating bladder carcinoma.

Furthermore, CCK-8 measurement and flow cytometry revealed that growth inhibition and apoptosis of EJ cells was greatest in the combination group, followed by the chemotherapy group, then the intervention group. These results suggest that transfection of EJ cells with siRNA Livin enhances the sensitivity of EJ cells to chemotherapeutic medications, which is consistent with a previous study using T24 human bladder cancer cells (5). The mechanism has been suggested to involve caspase-3 (2).

In summary of the present study, effective siRNA Livin was designed, which inhibited the expression and proliferation of Livin in EJ human bladder carcinoma cells, and promoted apoptosis. siRNA Livin also enhanced the sensitivity of EJ cells to MMC. These results provide a theoretical basis and experimental evidence to support therapy of bladder carcinoma using siRNA Livin.

Acknowledgements

This study was supported by grants from the Scientific Research Fund of Guangxi Provincial Education Department (grant no.'s 200911LX290, 200103YB092) and the Scientific Research and Technology Development Projects of Guilin City (grant no. 20100315-3).

References